In the AD hippocampus, NOTCH2NL, TGFB1I1, and LTF up-regulated, while ARPC1A, CHGB, and MPV17 down-regulated, indicating that the DEGs identified here can be used as AD pathological markers or potential treatment targets. This evidence concerns the gene CHGB and Alzheimer disease.